Xeris Biopharma Holdings Statistics
Total Valuation
XERS has a market cap or net worth of $1.56 billion. The enterprise value is $1.72 billion.
| Market Cap | 1.56B |
| Enterprise Value | 1.72B |
Important Dates
The next estimated earnings date is Thursday, August 6, 2026, before market open.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
XERS has 181.24 million shares outstanding. The number of shares has increased by 19.55% in one year.
| Current Share Class | 181.24M |
| Shares Outstanding | 181.24M |
| Shares Change (YoY) | +19.55% |
| Shares Change (QoQ) | -1.36% |
| Owned by Insiders (%) | 3.51% |
| Owned by Institutions (%) | 59.64% |
| Float | 174.88M |
Valuation Ratios
The trailing PE ratio is 134.16 and the forward PE ratio is 70.67.
| PE Ratio | 134.16 |
| Forward PE | 70.67 |
| PS Ratio | 5.01 |
| Forward PS | 3.86 |
| PB Ratio | 116.71 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 33.16 |
| P/OCF Ratio | 32.47 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 35.83, with an EV/FCF ratio of 36.25.
| EV / Earnings | 143.46 |
| EV / Sales | 5.47 |
| EV / EBITDA | 35.83 |
| EV / EBIT | 47.98 |
| EV / FCF | 36.25 |
Financial Position
The company has a current ratio of 2.12, with a Debt / Equity ratio of 19.87.
| Current Ratio | 2.12 |
| Quick Ratio | 1.42 |
| Debt / Equity | 19.87 |
| Debt / EBITDA | 4.61 |
| Debt / FCF | 5.44 |
| Interest Coverage | 1.25 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | 6.34% |
| Return on Invested Capital (ROIC) | 8.88% |
| Return on Capital Employed (ROCE) | 13.13% |
| Weighted Average Cost of Capital (WACC) | 8.91% |
| Revenue Per Employee | $723,800 |
| Profits Per Employee | $27,605 |
| Employee Count | 435 |
| Asset Turnover | 0.89 |
| Inventory Turnover | 0.70 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +68.30% in the last 52 weeks. The beta is 0.85, so XERS's price volatility has been lower than the market average.
| Beta (5Y) | 0.85 |
| 52-Week Price Change | +68.30% |
| 50-Day Moving Average | 7.08 |
| 200-Day Moving Average | 7.07 |
| Relative Strength Index (RSI) | 65.55 |
| Average Volume (20 Days) | 2,275,528 |
Short Selling Information
The latest short interest is 12.76 million, so 7.04% of the outstanding shares have been sold short.
| Short Interest | 12.76M |
| Short Previous Month | 12.81M |
| Short % of Shares Out | 7.04% |
| Short % of Float | 7.30% |
| Short Ratio (days to cover) | 6.20 |
Income Statement
In the last 12 months, XERS had revenue of $314.85 million and earned $12.01 million in profits. Earnings per share was $0.06.
| Revenue | 314.85M |
| Gross Profit | 270.44M |
| Operating Income | 35.90M |
| Pretax Income | 12.01M |
| Net Income | 12.01M |
| EBITDA | 48.08M |
| EBIT | 35.90M |
| Earnings Per Share (EPS) | $0.06 |
Balance Sheet
The company has $111.75 million in cash and $258.55 million in debt, with a net cash position of -$146.80 million or -$0.81 per share.
| Cash & Cash Equivalents | 111.75M |
| Total Debt | 258.55M |
| Net Cash | -146.80M |
| Net Cash Per Share | -$0.81 |
| Equity (Book Value) | 13.01M |
| Book Value Per Share | 0.08 |
| Working Capital | 133.09M |
Cash Flow
In the last 12 months, operating cash flow was $48.53 million and capital expenditures -$1.01 million, giving a free cash flow of $47.52 million.
| Operating Cash Flow | 48.53M |
| Capital Expenditures | -1.01M |
| Depreciation & Amortization | 12.18M |
| Net Borrowing | n/a |
| Free Cash Flow | 47.52M |
| FCF Per Share | $0.26 |
Margins
Gross margin is 85.89%, with operating and profit margins of 11.40% and 3.81%.
| Gross Margin | 85.89% |
| Operating Margin | 11.40% |
| Pretax Margin | 3.81% |
| Profit Margin | 3.81% |
| EBITDA Margin | 15.27% |
| EBIT Margin | 11.40% |
| FCF Margin | 15.09% |
Dividends & Yields
XERS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -19.55% |
| Shareholder Yield | -19.55% |
| Earnings Yield | 0.76% |
| FCF Yield | 3.02% |
Analyst Forecast
The average price target for XERS is $11.29, which is 31.28% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $11.29 |
| Price Target Difference | 31.28% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | 22.92% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
XERS has an Altman Z-Score of 0.79 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.79 |
| Piotroski F-Score | 7 |